Literature DB >> 12394209

Hepatocellular carcinoma: an epidemiologic view.

Hashem B El-Serag1.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and is estimated to cause approximately half a million deaths annually. Because of its high fatality rates, the incidence and mortality rates are almost equal. The major risk factors for HCC are chronic hepatitis B virus infection, chronic hepatitis C virus (HCV) infection, and alcoholic cirrhosis. The epidemiology of HCC is characterized by marked demographic (age, gender, race/ethnicity) and geographic variations. Hepatitis B virus infection, with and without aflatoxin exposure, is responsible for most cases in developing countries; better control of these risk factors has resulted in a recent decline in HCC in some places like Taiwan and China. Recently, however, a trend of rising rates of HCC has been reported from several developed countries in Europe and North America. These new trends are associated with "new" risk factors such as HCV and, possibly, diabetes. In the United States, the incidence of HCC has approximately doubled over the past 3 decades. White individuals are two to three times less often affected than African Americans, who in turn are two to three times less often affected than Asians, Pacific Islanders, or Native Americans. Men are two to three times more often affected than women. Concomitant with the rising rates of HCC, there has been a shift of incidence from typically elderly patients to relatively younger patients between ages of 40 to 60 years. An increase in HCV-related HCC accounts for at least half of the witnessed increase in HCC in the United States. Hepatocellular carcinoma continues to carry an overall dismal survival rate (close to 5%); very few patients qualify for and receive potentially curative therapy. The future incidence trends of HCC will be determined to a large extent by the clinical course of HCV-infected people.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12394209     DOI: 10.1097/00004836-200211002-00002

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  203 in total

1.  Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience.

Authors:  Mauro Borzio; Elena Dionigi; Angelo Rossini; Anna Toldi; Giampiero Francica; Fabio Fornari; Andrea Salmi; Fabio Farinati; Susanna Vicari; Massimo Marignani; Fulvia Terracciano; Barbara Ginanni; Rodolfo Sacco
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

2.  Little response of cerebral metastasis from hepatocellular carcinoma to any treatments.

Authors:  Jung Ho Han; Dong Gyu Kim; Jung Cheol Park; Hyun-Tai Chung; Sun Ha Paek; Young Seob Chung
Journal:  J Korean Neurosurg Soc       Date:  2010-05-31

3.  Surgical vs percutaneous radiofrequency ablation for hepatocellular carcinoma in dangerous locations.

Authors:  Ji-Wei Huang; Roberto Hernandez-Alejandro; Kristopher P Croome; Lu-Nan Yan; Hong Wu; Zhe-Yu Chen; Pankaj Prasoon; Yong Zeng
Journal:  World J Gastroenterol       Date:  2011-01-07       Impact factor: 5.742

4.  Differential Proteomic Analysis of Gender-dependent Hepatic Tumorigenesis in Hras12V Transgenic Mice.

Authors:  Zhuona Rong; Tingting Fan; Huiling Li; Juan Li; Kangwei Wang; Xinxin Wang; Jianyi Dong; Jun Chen; Fujin Wang; Jingyu Wang; Aiguo Wang
Journal:  Mol Cell Proteomics       Date:  2017-05-16       Impact factor: 5.911

5.  Screening for hepatocellular carcinoma by Egyptian physicians.

Authors:  Sahar M Hassany; Ehab F Abdou Moustafa; Mohamed El Taher; Afaf Adel Abdeltwab; Hubert E Blum
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

6.  miR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression.

Authors:  Caifeng Liu; Jun Li; Wei Wang; Xingyang Zhong; Feng Xu; Junhua Lu
Journal:  Cell Cycle       Date:  2020-04-14       Impact factor: 4.534

7.  B vitamins deficiency and decreased anti-oxidative state in patients with liver cancer.

Authors:  Chun-che Lin; Mei-chin Yin
Journal:  Eur J Nutr       Date:  2007-06-14       Impact factor: 5.614

8.  Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.

Authors:  Adel Abdel-Moneim; Alaa Aboud; Mohamed Abdel-Gabaar; Mohamed I Zanaty; Mohamed Ramadan
Journal:  Hepatol Int       Date:  2018-05-12       Impact factor: 6.047

9.  A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma.

Authors:  Song-I Bae; Jong Eun Yeon; Jong Mee Lee; Ji Hoon Kim; Hyun Jung Lee; Sun Jae Lee; Sang Jun Suh; Eileen L Yoon; Hae Rim Kim; Kwan Soo Byun; Tae-Seok Seo
Journal:  Clin Mol Hepatol       Date:  2012-09-25

10.  Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.

Authors:  Soichi Iritani; Kenji Imai; Koji Takai; Tatsunori Hanai; Takayasu Ideta; Tsuneyuki Miyazaki; Atsushi Suetsugu; Makoto Shiraki; Masahito Shimizu; Hisataka Moriwaki
Journal:  J Gastroenterol       Date:  2014-05-10       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.